Clinical trials are a milestone in the development of safe and effective drugs and therapies. An antibody developed by Helmholtz Munich is now entering a phase 1 clinical trial. Together with the radiopharmaceutical company ITM Isotope Technologies…
Amyotrophic Lateral Sclerosis (ALS) is a non-curable degenerative disease of the motor nervous system. The cause of the disease is largely unknown: In addition to genetic factors, viruses are also suspected to be involved in the development of the…
The Bavarian State Government appoints Helmholtz Munich researcher Claudia Traidl-Hoffmann as special representative for climate resilience and prevention. The Bavarian Minister of Health, Klaus Holetschek, will present the special representative and…
Helmholtz Munich researcher Dr Vincent Fortuin is one of the young investigator group leaders at Helmholtz AI. His work focuses on the interface between Bayesian inference and deep learning. Bayesian inference is a statistical method to learn from…
The pandemic, war, or climate change are stressful for many people. In response to stress, the body’s own hormones glucocorticoids are released. High stress hormone levels are associated with metabolic disease and aging, whereas dieting might…
Every year, the Bayer Foundation awards the Early Excellence in Science Award. This year’s winner in the category “Data Science in the Life Sciences” is Helmholtz Munich researcher Mohammad Lotfollahi from the Institute of Computational Biology. With…
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here: